Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151259 | 0.91 | NAMPT (0.34) | NAMPTKMT2AMEN1TACR1 | |
| SCHEMBL24974548 | 0.89 | KMT2A (0.37) | MAPK1RAB9ANAMPTKMT2ATP53 | |
| SCHEMBL21151158 | 0.89 | NAMPT (0.33) | NAMPTTACR1 | |
| SCHEMBL21150845 | 0.89 | NAMPT (0.34) | NAMPTITGB3ITGA2BTACR1 | |
| SCHEMBL21151201 | 0.88 | MCHR1 (0.38) | MAPK1NAMPT | |
| SCHEMBL21152140 | 0.88 | ENPP2 (0.35) | NAMPTTACR1 | |
| SCHEMBL21150858 | 0.88 | NAMPT (0.36) | NAMPT | |
| SCHEMBL21150848 | 0.87 | NAMPT (0.34) | NAMPTITGB3ITGA2BTACR1 | |
| SCHEMBL24974528 | 0.87 | MAPK1 (0.33) | MAPK1NAMPTITGB3ITGA2BTACR1 | |
| SCHEMBL21151783 | 0.86 | NAMPT (0.33) | MAPK1NAMPTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | MAPK1 3778/4885RAB9A 2444/4885NAMPT 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.